Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas

Gene Therapy

Volumn 12, Issue 5, 2005, Pages 407-417

  Kaliberov, S A ^a   Kaliberova, L N ^a   Buchsbaum, D J ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

Gene therapy; Ionizing radiation; Prostate cancer; sKDR; VEGF

Indexed keywords

ADENOVIRUS VECTOR; RADIOSENSITIZING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL MIGRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; ENDOTHELIUM CELL; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MITOSIS INHIBITION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SOLUBILITY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ADENOVIRIDAE;

EID: 15444379976     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302432     Document Type: Article

References (54)

1. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003; 29: 171-187.
2. Parker CC, Dearnaley DP. Radical radiotherapy for prostate cancer. Cancer Treat Rev 2003; 29: 161-169.
3. Teh BS et al. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist 2002; 7: 458-466.
4. Kawashita Y et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum Gene Ther 1999; 10: 1509-1519.
5. Atkinson G, Hall SJ. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology 1999; 54: 1098-1104.
6. Stevens CW, Zeng M, Cerniglia GJ. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum Gene Ther 1996; 7: 1727-1734.
7. Zeng M et al. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther 1997; 8: 1025-1032.
8. Jain PT, Gewirtz DA. Sustained enhancement of liposome-mediated gene delivery and gene expression in human breast tumour cells by ionizing radiation. Int J Radiat Oncol Biol Phys 1999; 75: 217-223.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1995; 1: 27-31.
10. Dvorak HF et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991; 174: 1275-1278.
11. Plate KH et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993; 53: 5822-5827.
12. Ferrer FA et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer. J Urol 1997; 157: 2329-2333.
13. Ferrer FA et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51: 161-167.
14. Shibuya M et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-524.
15. Terman BI et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-1586.
16. de Vries C et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
17. Waltenberger J et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-26995.
18. Seetharam L et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10: 135-147.
19. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999; 126: 3015-3025.
20. Terman B et al. VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor. Growth Factors 1994; 11: 187-195.
21. Clauss M et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629-17634.
22. Soker S et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745.
23. Melnyk O, Zimmerman M, Jin Kim K, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999; 161: 960-963.
24. Kim KJ et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
25. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709.
26. Aiello LP et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461.
27. Strawn LM et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540-3545.
28. Collis SJ, Khater K, DeWeese TL. Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World J Urol 2003; 21: 275-289.
29. Thurman SA, Ramakrishna NR, DeWeese TL. Radiation therapy for the treatment of locally advanced and metastatic prostate cancer. Hematol Oncol Clin North Am 2001; 15: 423-443.
30. Weidner N et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143 401-409.
31. Bettencourt MC et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998; 160: 459-465.
32. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78: 940-944.
33. Mydlo JH et al. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications. Eur Urol 1998; 34: 426-432.
34. Sternberg CN. What's new in the treatment of advanced prostate cancer? Eur J Cancer 2003; 39: 136-146.
35. Lin P et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998; 9: 49-58.
36. Leunig M et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174 T in SCID mice. Cancer Res 1992; 52: 6553-6560.
37. Goldman C et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rat. Proc Natl Acad Sci USA 1998; 95: 8795-8800.
38. Kendall R, Wang G, DiSalvo J, Thomas K. Specificity of vascular endothelial cell growth factor receptor ligand binding domains. Biochem Biophys Res Commun 1994; 201: 326-330.
39. Kendall R, Wang G, Thomas K. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324-328.
40. Abdollahi A et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003; 63: 3755-3763.
41. Park JS et al. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 2001; 20 3266-3280.
42. Ma BB, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 2003; 21: 2760-2776.
43. Garcia-Barros M et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-1159.
44. Masood R et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904-1913.
45. Jackson MW et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002; 62: 854-859.
46. Khodarev NN et al. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003; 116 1013-1022.
47. Vega-Diaz B, Herron GS, Michel S. An autocrine loop mediates expression of vascular endothelial growth factor in human dermal microvascular endothelial cells. J Invest Dermatol 2001; 116: 525-530.
48. Milanini J et al. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998; 273: 18165-18172.
49. Seko Y et al. Vascular endothelial growth factor (VEGF) activates Raf-1, mitogen-activated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes. J Cell Physiol 1998; 175: 239-246.
50. Mahasreshti PJ et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003; 9: 2701-2710.
51. Ng IO et al. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001; 116: 838-845.
52. Zhao J et al. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. Chin Med J (Engl) 2003; 116: 772-776.
53. Shi B, Wang X, Yang Z. Vascular endothelial growth factors and liver diseases. Hepatogastroenterology 2001; 48: 1145-1148.
54. Kaliberov SA et al. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol Ther 2002; 6: 190-198.